Newly established Mainz Center for Chemical Allergology investigates the chemical basis of allergies
Cooperation of the Max Planck Institute for Chemistry and the Mainz University Medical Center
19.06.2015Researchers of the Max Planck Institute for Chemistry and the Institute of Translational Immunology (TIM) of the Mainz University Medical Center have recently begun to work together in a newly created platform: In the Mainz Center for Chemical Allergology (MCCA) scientists from both institutes jointly investigate to which extent pollutants in the atmosphere or the change in the composition of foods worsen allergies. This requires a deeper understanding of how allergens are modified by the environment and thus induce an altered body's immune responses. The research aims at creating the base for a better understanding of the constantly increasing number of hypersensitivities and at delineating paths for effective treatments and targeted preventative measures.
The MCCA was initiated by Professor Ulrich Pöschl, director of the Multiphase Chemistry Department and managing director of the Max Planck Institute for Chemistry in Mainz, and Professor Detlef Schuppan, head of the Institute of Translational Immunology at the University Medical Center of Johannes Gutenberg University Mainz (JGU). The scientists and physicians at the MCCA hope for a rapid progress in research on allergies and other hypersensitivities through the bundling of their expertise, which is unique in this form.
"Studies have shown that previously known allergens can change as a result of pollution or cultivation conditions and the growing of crops, which we were able to demonstrate, for example, in wheat. Their characteristics can be modified and thus also the type and severity of allergies and hypersensitivities they trigger," said Professor Detlef Schuppan, explaining the research approach of the interdisciplinary center. The physician had discovered that the increased content of the so-called amylase trypsin inhibitors in cereals containing gluten can worsen allergies and autoimmune diseases.
"With the designation 'chemical allergology' we have created a new term. It describes that we do not only want to determine empirical relationships, but we also want to clarify fundamental chemical processes which are responsible for the occurrence of allergies and the influence of pollutants," said Professor Ulrich Pöschl, describing the relationship between the research center and its naming.
Dr. Kurt Lucas, group head of the Multiphase Chemistry Department, has assumed the operative leadership for the Max Planck Institute for Chemistry. PD Dr. Ernesto Bockamp heads the molecular biological part of the initiative for the Institute of Translational Immunology.
Currently, the researchers are working on two subject fields together with three PhD students. On the one side, the scientists want to find out how specific inflammation processes, which worsen allergies and hypersensitivities, can be inhibited or interrupted in the human body by means of plant ingredients. "The basis for our research is the discovery that the majority of inflammatory processes in the body show a universal molecular cycle process", explained Dr. Kurt Lucas. He refers to allergy-related asthma and autoimmune diseases such as rheumatism, multiple sclerosis, and inflammatory bowel diseases.
Furthermore, the scientists of the MCCA are exploring the fundamental questions of what exactly turns a substance into an effective allergen or immunogen. To this end, they are studying immune-stimulating molecular characteristics of allergens to better define why certain substances trigger the formation of antibodies or cell responses resulting in an allergy. The focus lies on the type and extent to which the inflammation-promoting effect of known pollen or food allergens is increased by chemical changes. For example, allergens can be chemically altered by ozone or nitrogen oxide in the atmosphere, but also by catalytic reactions that are promoted on microscopic dust particles.
Although the scientists have only recently started their joint investigations, they have already obtained promising first results. In particular, they could identify a number of anti-inflammatory plant extracts that inhibit specific cellular inflammation sensors, the so-called toll-like receptors (TLRs). Currently the active ingredients of these extracts are being characterized.